A new program aims to help stroke survivors change their lives

NCT ID NCT07761130

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study tests whether a program called iHeLP is practical and acceptable for stroke survivors. The program includes a one-on-one interview to set personal goals, followed by six weekly group sessions focused on healthy lifestyle changes. Researchers will measure how many people join and stick with the program, and whether it improves participants' lifestyle behaviors. The goal is to see if this approach could support stroke survivors in reducing their risk of future health problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
The Improving Health and Lifestyle Programme (iHeLP), a behavioral intervention involving a one-to-one interview and six weekly group sessions to support healthy lifestyle changes after stroke.
What this could lead to
If successful, this program could offer a practical way to help stroke survivors adopt and maintain healthier lifestyles, potentially reducing the risk of future strokes.
What could go wrong
This is a small feasibility study, so it may not prove the program's effectiveness. Results may not generalize to all stroke survivors, and participation requires commitment to multiple sessions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Irish Heart Foundation

    Dublin, Leinster, Ireland

  • University of Limerick

    Limerick, Munster, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.